|
[1] JUMP DB,DEPNER CM,SASMITA T,et al. Potential for dietaryω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer[J]. Adv Nutr,2015,6(6):694-702.
|
|
[2] NOBILI V,ALISI A,MUSSO G,et al. Omega-3 fatty acids:Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD[J]. Clin Lab Sci,2016,53(2):106-120.
|
|
[3] PAWAR A,JUMP DB. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptorαactivity in rat primary hepatoctes[J]. J Biol Chem,2003,278(38):35931-35939.
|
|
[4] JUMP DB,TRIPATHY S,DEPNER CM. Fatty acid-regulated transcription factors in the liver[J]. Annu Rev Nutr,2013,33:249-269.
|
|
[5] LAMBERT JE,RAMOS-ROMAN MA,BROWNING JD,et al.Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease[J]. Gastroenterology,2014,146(3):726-735.
|
|
[6] PAGLIALUNGA S,DEHN CA. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease[J].Lipids Health Dis,2016,15(1):159.
|
|
[7] GNONI A,GIUDETTI AM. Dietary long-chain unsaturated fatty acids acutely and differently reduce the activities of lipogenic enzymes and of citrate carrier in rat liver[J]. J Physiol Biochem,2016,72(3):485-494.
|
|
[8] SCORLETTI E,BYRNE CD. Omega-3 fatty acids and nonalcoholic fatty liver disease:Evidence of efficacy and mechanism of action[J]. Mol Aspects Med,2018,64:135-146.
|
|
[9] LYTLE KA,WONG CP,JUMP DB. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/-mice[J]. PLo S One,2017,12(4):e0173376-e0173376.
|
|
[10] DEPNER CM,TRABER MG,BOBE G,et al. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/-mice[J]. PLo S One,2013,8(12):e83756-e83756.
|
|
[11] DEPNER CM,PHILBRICK KA,JUMP DB. Docosahexaenoic acid attenuates hepatic inflammation,oxidative stress,and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-)mouse model of western diet-induced nonalcoholic steatohepatitis[J]. J Nutr,2013,143(3):315-323.
|
|
[12] LYTLE KA,DEPNER CM,WONG CP,et al. Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr-/-mice by targeting the TGFβ-Smad3 pathway[J]. J Lipid Res,2015,56(10):1936-1946.
|
|
[13] WATSON H,MITRA S,CRODEN FC,et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota[J]. Gut,2017,67(11):1974-1983.
|
|
[14] PROVENZANO A,MILANI S,VIZZUTTI F,et al. n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis[J]. Liver Int,2014,34(6):918-930.
|
|
[15] BOYRAZ M,PIRGON，DNDAR B,et al. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease[J]. J Clin Res Pediatr Endocrinol,2015,7(2):121-127.
|
|
[16] NOGUEIRA MA,OLIVEIRA CP,FERREIRA ALVES VA,et al.Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis:A randomized,double-blind,placebo-controlled trial[J]. Clin Nutr,2016,35(3):578-586.
|
|
[17] TOBIN D,BREVIK-ANDERSEN M,QIN Y,et al. Evaluation of a high concentrate omega-3 for correcting the omega-3fatty acid nutritional deficiency in non-alcoholic fatty liver disease(CONDIN)[J]. Nutrients,2018,10(8):1126-1126.
|
|
[18] DASARATHY S,DASARATHY J,KHIYAMI A,et al. Doubleblind randomized placebo-controlled clinical trial of omega 3fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis[J]. J Clin Gastroenterol,2015,49(2):137-144.
|
|
[19] KARLAS T,PETROFF D,SASSO M,et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis[J]. J Hepatol,2017,66(5):1022-1030.
|
|
[20] TUTINO V,de NUNZIO V,CARUSO MG,et al. Aerobic physical activity and a low glycemic diet reduce the aa/epa ratio in red blood cell membranes of patients with NAFLD[J]. Nutrients,2018,10(9). pii:E1299
|
|
[21] SOFI F,GIANGRANDI I,CESARI F,et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients:A preliminary study[J]. Int J Food Sci Nutr,2010,61(8):792-802.
|
|
[22] HE XX,WU XL,CHEN RP,et al. Effectiveness of omega-3polyunsaturated fatty acids in non-alcoholic fatty liver disease:A Meta-analysis of randomized controlled trials[J].PLo S One,2016,11(10):e0162368-e0162368.
|
|
[23] LU W,LI S,LI J,et al. Effects of omega-3 fatty acid in nonalcoholic fatty liver disease:A Meta-analysis[J]. Gastroenterol Res Pract,2016,2016:1459790-1459790.
|
|
[24] PARKER HM,JOHNSON NA,BURDON CA,et al. Omega-3supplementation and non-alcoholic fatty liver disease:A systematic review and meta-analysis[J]. J Hepatol,2012,56(4):944-951.
|
|
[25] KLEINER DE,BEDOSSA P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists[J]. Gastroenterology,2015,149(6):1305-1308.
|
|
[26] NOBILI V,BEDOGNI G,ALISI A,et al. Docosahexaenoic acid supplementation decreases liver fat content in children with nonalcoholic fatty liver disease:Double-blind randomised controlled clinical trial[J]. Arch Dis Child,2011,96(4):350-353.
|
|
[27] PACIFICO L,BONCI E,di MARTINO M,et al. A doubleblind,placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease[J]. Nutr Metab Cardiovasc Dis,2015,25(8):734-741.
|
|
[28] MACHANN J,THAMER C,SCHNOEDT B,et al. Hepatic lipid accumulation in healthy subjects:A comparative study using spectral fat-selective MRI and volume-localized1H-MR spectroscopy[J]. Magn Reson Med,2006,55(4):913-917.
|
|
[29] SCORLETTI E,WEST A L,BHATIA L,et al. Treating liver fat and serum triglyceride levels in NAFLD,effects of PNPLA3 and TM6SF2 genotypes:Results from the WELCOME trial[J]. J Hepatol,2015,63(6):1476-1483.
|
|
[30] ALLAIRE J,COUTURE P,LECLERC M,et al. A randomized,crossover,head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women:The Comparing EPA to DHA(ComparED)Study[J]. Am J Clin Nutr,2016,104(2):280-287.
|
|
[31] PARK HG,LAWRENCE P,ENGEL MG,et al. Metabolic fate of docosahexaenoic acid(DHA; 22:6n-3)in human cells:Direct retroconversion of DHA to eicosapentaenoic acid(20:5n-3)dominates over elongation to tetracosahexaenoic acid(24:6n-3)[J]. FEBS Lett,2016,590(18):3188-3194.
|
|
[32] SANYAL AJ,ABDELMALEK MF,SUZUKI A,et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 tria L[J].Gastroenterology,2014,147(2):377-384.
|
DownLoad: